These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
184 related articles for article (PubMed ID: 38638911)
21. The microbial diversity following antibiotic treatment of Clostridioides difficile infection. Binyamin D; Nitzan O; Azrad M; Hamo Z; Koren O; Peretz A BMC Gastroenterol; 2021 Apr; 21(1):166. PubMed ID: 33849457 [TBL] [Abstract][Full Text] [Related]
22. Integrating gut microbiome and host immune markers to understand the pathogenesis of Ke S; Pollock NR; Wang XW; Chen X; Daugherty K; Lin Q; Xu H; Garey KW; Gonzales-Luna AJ; Kelly CP; Liu YY Gut Microbes; 2021; 13(1):1-18. PubMed ID: 34132169 [No Abstract] [Full Text] [Related]
23. Inhibiting Growth of Clostridioides difficile by Restoring Valerate, Produced by the Intestinal Microbiota. McDonald JAK; Mullish BH; Pechlivanis A; Liu Z; Brignardello J; Kao D; Holmes E; Li JV; Clarke TB; Thursz MR; Marchesi JR Gastroenterology; 2018 Nov; 155(5):1495-1507.e15. PubMed ID: 30025704 [TBL] [Abstract][Full Text] [Related]
24. Clearance of Clostridioides difficile Colonization Is Associated with Antibiotic-Specific Bacterial Changes. Lesniak NA; Schubert AM; Sinani H; Schloss PD mSphere; 2021 May; 6(3):. PubMed ID: 33952668 [TBL] [Abstract][Full Text] [Related]
25. Risk factors and intestinal microbiota: Clostridioides difficile infection in patients receiving enteral nutrition at Intensive Care Units. Wang D; Dong D; Wang C; Cui Y; Jiang C; Ni Q; Su T; Wang G; Mao E; Peng Y Crit Care; 2020 Jul; 24(1):426. PubMed ID: 32660525 [TBL] [Abstract][Full Text] [Related]
27. Gut microbiome and mycobiome in inflammatory bowel disease patients with Yu S; Ge X; Xu H; Tan B; Tian B; Shi Y; Dai Y; Li Y; Hu S; Qian J Front Cell Infect Microbiol; 2023; 13():1129043. PubMed ID: 36814443 [TBL] [Abstract][Full Text] [Related]
28. Ceragenin CSA13 Reduces Clostridium difficile Infection in Mice by Modulating the Intestinal Microbiome and Metabolites. Wang J; Ghali S; Xu C; Mussatto CC; Ortiz C; Lee EC; Tran DH; Jacobs JP; Lagishetty V; Faull KF; Moller T; Rossetti M; Chen X; Koon HW Gastroenterology; 2018 May; 154(6):1737-1750. PubMed ID: 29360463 [TBL] [Abstract][Full Text] [Related]
30. Candida gut colonization, yeast species distribution, and biofilm production in Clostridioides difficile infected patients: a comparison between three populations in two different time periods. Brunetti G; Giuliani A; Navazio AS; Paradisi C; Raponi F; Conti LA; Raponi G Braz J Microbiol; 2021 Dec; 52(4):1845-1852. PubMed ID: 34264501 [TBL] [Abstract][Full Text] [Related]
31. Insight into alteration of gut microbiota in Clostridium difficile infection and asymptomatic C. difficile colonization. Zhang L; Dong D; Jiang C; Li Z; Wang X; Peng Y Anaerobe; 2015 Aug; 34():1-7. PubMed ID: 25817005 [TBL] [Abstract][Full Text] [Related]
32. Pre-colonization with the fungus Romo JA; Tomihiro M; Kumamoto CA mSphere; 2023 Aug; 8(4):e0012223. PubMed ID: 37358292 [TBL] [Abstract][Full Text] [Related]
33. The interplay between microbiome dynamics and pathogen dynamics in a murine model of Clostridium difficile Infection. Reeves AE; Theriot CM; Bergin IL; Huffnagle GB; Schloss PD; Young VB Gut Microbes; 2011; 2(3):145-58. PubMed ID: 21804357 [TBL] [Abstract][Full Text] [Related]
34. The contribution of bile acid metabolism to the pathogenesis of Mullish BH; Allegretti JR Therap Adv Gastroenterol; 2021; 14():17562848211017725. PubMed ID: 34104212 [No Abstract] [Full Text] [Related]
35. High Dose Intramuscular Vitamin D3 Supplementation Impacts the Gut Microbiota of Patients With Lee SH; Park HK; Kang CD; Choi DH; Park SC; Park JM; Nam SJ; Chae GB; Lee KY; Cho H; Lee SJ Front Cell Infect Microbiol; 2022; 12():904987. PubMed ID: 35774395 [TBL] [Abstract][Full Text] [Related]
36. Proton Pump Inhibitor-Induced Gut Dysbiosis Increases Mortality Rates for Patients with Clostridioides difficile Infection. Lin CY; Cheng HT; Kuo CJ; Lee YS; Sung CM; Keidan M; Rao K; Kao JY; Hsieh SY Microbiol Spectr; 2022 Aug; 10(4):e0048622. PubMed ID: 35863023 [TBL] [Abstract][Full Text] [Related]
37. Integrated Meta-omics Reveals a Fungus-Associated Bacteriome and Distinct Functional Pathways in Clostridioides difficile Infection. Stewart DB; Wright JR; Fowler M; McLimans CJ; Tokarev V; Amaniera I; Baker O; Wong HT; Brabec J; Drucker R; Lamendella R mSphere; 2019 Aug; 4(4):. PubMed ID: 31462412 [TBL] [Abstract][Full Text] [Related]
38. The protective effect of recombinant Lactococcus lactis oral vaccine on a Clostridium difficile-infected animal model. Yang XQ; Zhao YG; Chen XQ; Jiang B; Sun DY BMC Gastroenterol; 2013 Jul; 13():117. PubMed ID: 23865596 [TBL] [Abstract][Full Text] [Related]
39. Systemic Inflammatory Mediators Are Effective Biomarkers for Predicting Adverse Outcomes in Clostridioides difficile Infection. Dieterle MG; Putler R; Perry DA; Menon A; Abernathy-Close L; Perlman NS; Penkevich A; Standke A; Keidan M; Vendrov KC; Bergin IL; Young VB; Rao K mBio; 2020 May; 11(3):. PubMed ID: 32371595 [No Abstract] [Full Text] [Related]
40. CDBN-YGXZ, a Novel Small-Molecule Drug, Shows Efficacy against Clostridioides difficile Infection and Recurrence in Mouse and Hamster Infection Models. Hu X; Dong R; Huang S; Zeng Y; Zhan W; Gao X; Tian D; Peng J; Xu J; Wang T; Zhang Y; Wang X; Zhang X; Liu J; Guang B; Yang T Antimicrob Agents Chemother; 2023 May; 67(5):e0170422. PubMed ID: 37052498 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]